share_log

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

Chemomab Treateutics第二季度每股收益$(0.03)超过$(0.25)预期
Benzinga Real-time News ·  2022/08/12 06:04

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.25) by 88 percent. This is a 88.46 percent increase over losses of $(0.26) per share from the same period last year.

化学单抗治疗公司(纳斯达克代码:CMMB)公布季度亏损为每股0.03美元,比分析师普遍预期的0.25美元高出88%。这比去年同期每股亏损0.26美元增加了88.46%。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发